Carlos Buznego, MD
Ophthalmology · Miami, FLNPI 1851512354
Payments from drug & device makers
Across 1,094 payments — averaging $276.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$91K
- Kala Pharmaceuticals, Inc.$64K
- Lensar, Inc.$23K
- Harrow Eye, LLC$22K
- Sun Pharmaceutical Industries Inc.$20K
- Aerie Pharmaceuticals, Inc.$18K
- plus $64K from 43 others
Across 1 payment — averaging $3769.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$4K
What the payments were for
- Consulting fees$99,56435%
- Speaking & faculty fees$126,95744%
- Travel & lodging$16,6296%
- Food & beverage$43,92015%
- Education$800%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVELTYS$35,962
- iStent inject Trabecular Micro-Bypass Stent System$24,180
- LENSAR LASER SYSTEM$22,397
- VEVYE$21,468
- iStent inject W$18,351
- EYSUVIS$18,092
- Rhopressa$17,271
- Rocklatan$17,271
- OMNI(R) SURGICAL SYSTEM (US)$14,120
- BROMSITE$11,570
- iDose$9,064
- CEQUA$6,633
- ENVISTA ENVY IOL$6,487
- Crystalens Accommodating IOL (AT-52AO)$6,375
- enVista MX60 IOL$3,825
- Ahmed Glaucoma Valve$3,433
- Kahook Dual Blade$3,433
- iStent Trabecular Micro-Bypass Stent System$3,232
- OCT OPHTHALMOSCOPE$3,000
- DURYSTA$2,892
How this compares
$302,408 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 365 | $345,363 |
| LumiganBimatoprost | 178 | $65,261 |
| XiidraLifitegrast | 39 | $37,910 |
| RhopressaNetarsudil Mesylate | 60 | $22,340 |
| Latanoprost | 3,014 | $20,118 |
| VyzultaLatanoprostene Bunod | 33 | $14,279 |
| CombiganBrimonidine Tartrate/Timolol | 28 | $13,344 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 33 | $12,080 |
| ProlensaBromfenac Sodium | 27 | $9,621 |
| Cyclosporine | 15 | $9,563 |
| Travoprost | 61 | $7,124 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 790 | $6,808 |
| Brimonidine Tartrate | 191 | $6,600 |
| Prednisolone Acetate | 136 | $6,144 |
| Timolol Maleate | 550 | $5,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $7,634 | $429,377591 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $14,883 | $52,18972 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $17,901 | $27,84776 claims |
| AlconSimbrinza | $3,702 | $12,08033 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $253 | $9,62127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Miami
- Guillermo AmescuaMiami$962K
- Felipe MedeirosMiami$935K
- Jennifer LohMiami$606K
- Jaclyn KovachMiami$590K
- William TrattlerMiami$580K
- Wilfredo LaraMiami$526K
- Jayanth SridharMiami$525K
- Kendall DonaldsonMiami$351K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.